216 related articles for article (PubMed ID: 38741073)
1. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
2. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
4. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
5. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
7. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
8. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
Kim MH; Kim J
Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
[TBL] [Abstract][Full Text] [Related]
9. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic significance of YAP, TAZ, TEAD4 and p73 in human laryngeal cancer.
Tsinias G; Nikou S; Mastronikolis N; Bravou V; Papadaki H
Histol Histopathol; 2020 Sep; 35(9):983-995. PubMed ID: 32378727
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Corvaisier M; Bauzone M; Corfiotti F; Renaud F; El Amrani M; Monté D; Truant S; Leteurtre E; Formstecher P; Van Seuningen I; Gespach C; Huet G
Oncotarget; 2016 Aug; 7(35):56699-56712. PubMed ID: 27527859
[TBL] [Abstract][Full Text] [Related]
13. Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass.
Choi S; Kang JG; Tran YTH; Jeong SH; Park KY; Shin H; Kim YH; Park M; Nahmgoong H; Seol T; Jeon H; Kim Y; Park S; Kim HJ; Kim MS; Li X; Bou Sleiman M; Lee E; Choi J; Eisenbarth D; Lee SH; Cho S; Moore DD; Auwerx J; Kim IY; Kim JB; Park JE; Lim DS; Suh JM
Nat Metab; 2024 May; 6(5):847-860. PubMed ID: 38811804
[TBL] [Abstract][Full Text] [Related]
14. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
15. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
16. β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer.
San Millán C; Soldevilla B; Martín P; Gil-Calderón B; Compte M; Pérez-Sacristán B; Donoso E; Peña C; Romero J; Granado-Lorencio F; Bonilla F; Domínguez G
Clin Cancer Res; 2015 Oct; 21(19):4398-409. PubMed ID: 26023082
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
18. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
19. Lats1 and Lats2 regulate YAP and TAZ activity to control the development of mouse Sertoli cells.
Abou Nader N; Charrier L; Meisnsohn MC; Banville L; Deffrennes B; St-Jean G; Boerboom D; Zamberlam G; Brind'Amour J; Pépin D; Boyer A
FASEB J; 2024 May; 38(9):e23633. PubMed ID: 38690712
[TBL] [Abstract][Full Text] [Related]
20. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
